Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-Spectroscopy: Neurochemical changes in migraineurs treated with CGRP antibody
2021-006219-28Phase 4Active
- Sponsor
- Medical University of Innsbruck
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fremanezumab in episodic migraine (2 arms), sponsored by Medical University of Innsbruck. Primary endpoint: Neurochemical changes in brain metabolism. Started Jan 2022; status: active.
02
Drugs
fremanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on 2021-006219-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006219-28.